drugset
drugset / Trial / NCT00830518

A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome

NCT00830518 ↗

Phase 2 Completed 57 enrolled Millennium Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, phase 2 study of alisertib (MLN8237) in participants with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Timeline

Start
2009-02-10
Primary completion
2010-02-02
Completion
2011-07-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Alisertib Small molecule 50 mg Oral

Indications

acute myeloid leukemia myelodysplastic syndrome